Evidence map›Paper›PMID 34943636›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Detection and Outcome of Endocervical Atypia in Cytology in Primary HPV Screening Programme.

Johanna Pulkkinen, Saara Kares, Heini Huhtala, Ivana Kholová

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Johanna PulkkinenPathology, Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.
Saara KaresPathology, Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.
Heini HuhtalaFaculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.ORCID 0000-0003-1372-430X
Ivana KholováPathology, Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.ORCID 0000-0003-4089-0450
Fimlab (Finland) · FITampere University · FI

Funding

Competitive Research Funding of the Pirkanmaa Hospital District X5211
6 · The paper itself

Abstract

Most endocervical adenocarcinomas (EAC) are associated with high-risk HPV (hrHPV) infection, with HPV genotypes 16, 18 and 45 accounting for >90% of the cases. Among endocervical glandular lesions, screening with hrHPV test has previously shown to predict the outcome better than cytology, although around one-fifth of the EAC remain negative both in hrHPV testing and cytology. The study consists of two consecutive HPV-primary screening rounds, conducted in 2012-2015 and 2017-2020. Of the 87 women aged 35 to 60 years of age diagnosed with Atypical endocervical cells, NOS or Atypical endocervical cells, favor neoplastic cytology during the first screening round, 63 (72.4%) were hrHPV positive and 24 (27.6%) were hrHPV negative. Among hrHPV positive patients, three EAC, two adenocarcinomas in situ (AIS), one AIS + high-grade intraepithelial lesion (HSIL) and 13 HSIL were found. Of the histologically verified lesions, 68.4% (13/19) were purely of squamous origin. All the EAC and AIS were HPV16 or HPV 18 positive. No high-grade histological lesions were found among the hrHPV negative patients with cytological glandular atypia. A later database search revealed one HPV-negative, gastric-type mucinous EAC that was missed by the HPV primary screening.

Indexed as

adenocarcinoma in situatypical endocervical cellscytologyendocervical adenocarcinomaHPVscreening

Identifiers

PMID34943636
PMCPMC8700048
OpenAlexW4200054441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.